Skip to main content

Neurogene Inc.

corporate_fare Company Profile

Neurogene Inc.

NGNE·NASDAQ·Life Sciences·CIK 0001404644

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases that are not treatable by conventional gene therapy. The company aims to address the challenges of complex neurological disease biology and variable gene uptake and expression. Neurogene Inc. utilizes its proprietary transgene regulation technology, EXACT™ (Expression Attenuation via Construct Tuning), which employs microRNA-based genetic circuits. This technology is designed to deliver therapeutic levels of transgenes to specific brain areas involved in neurological disease pathology. Neurogene Inc.'s primary clinical-stage program is NGN-401, which is being developed for the treatment of Rett syndrome. NGN-401 uses the EXACT technology and adeno-associated virus (AAV) delivery. Rett syndrome is a severe and progressive neurodevelopmental disease causing significant neurological and physical impairment. The company's ongoing registrational trial for NGN-401, named Embolden™, is a single-arm, open-label, baseline-controlled trial. This trial is evaluating the 1E15 vg dose of NGN-401 in 20 females with Rett syndrome, aged three and above. Embolden has enrolled 100% of participants, and more than 50% of participants have been dosed. Dosing is expected to be completed in the second quarter of 2026. Neurogene Inc. also completed dosing in a Phase 1/2 open-label, multi-center clinical trial of NGN-401 for Rett syndrome, where ten participants received the 1E15 vg dose. NGN-401 is administered via a one-time intracerebroventricular (ICV) procedure.

Neurogene Inc. (NASDAQ:NGNE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NGNE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FDA Grants Breakthrough Therapy Designation to Neurogene's NGN-401 for Rett Syndrome
  • Neurogene's NGN-401 Gene Therapy for Rett Syndrome Receives FDA Breakthrough Therapy Designation
  • Neurogene Advances Rett Syndrome Gene Therapy NGN-401 with Registrational Trial Progress and Strong Cash Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$90.35M
Diluted EPS
-$4.24
Op. Cash Flow
-$77.17M
Free Cash Flow
-$78.36M
Operating Income
-$103.33M
Cash & Equivalents
$103.84M
Debt / Equity
0.00×
Shares Outstanding
15.49M sh
Source: 10-K · filed 2026-03-24 · accession 0001404644-26-000019
$22.15
52-week range · as of 2026-11-09 $15.93 – $43.66
Market cap
$458.53M
Volume
178.3K (0.6× avg)
3-mo avg 316.4K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NGNE - Filings & News (Page 2)

NGNE
Mar 24, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $19.36
Real-time Price: $22.15 info
Change: +$2.79 (+14%) info
Market Cap: $458.525M info
NGNE
Feb 26, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $21.24
Real-time Price: $22.15 info
Change: +$0.910 (+4%) info
Market Cap: $458.525M info
NGNE
Jan 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.29
Real-time Price: $22.15 info
Change: +$3.86 (+21%) info
Market Cap: $458.525M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets